A Phase III, Open-label, Randomized Study of the Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer

Trial Profile

A Phase III, Open-label, Randomized Study of the Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer

Suspended
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Cisplatin (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Orient Europharma
  • Most Recent Events

    • 10 Aug 2017 According to a NanoCarrier media release, Registration of new patients was suspended temporarily due to the effects of the cancellation of the Phase I clinical trials in Japan for combination therapy with radiation for the indication of head and neck cancer, but the company is planning to restart registration of new patients in April 2017.
    • 10 Aug 2017 Status changed from recruiting to suspended, as reported in a NanoCarrier media release.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top